HER2-positive Endometrial Cancer
1 clinical trials · Condition
◉ Watch HER2-positive Endometrial Cancer
| Record | Firm | Date |
|---|---|---|
| A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors (NCT04278144) | Bolt Biotherapeutics, Inc. | 2020-02-24 |
Track HER2-positive Endometrial Cancer automatically
Every clearance here is in the API, with alerts when new ones post.